IN2013MU02470A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02470A
IN2013MU02470A IN2470MU2013A IN2013MU02470A IN 2013MU02470 A IN2013MU02470 A IN 2013MU02470A IN 2470MU2013 A IN2470MU2013 A IN 2470MU2013A IN 2013MU02470 A IN2013MU02470 A IN 2013MU02470A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Shafiq Sheikh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN2470MU2013 priority Critical patent/IN2013MU02470A/en
Priority to BR112015031878A priority patent/BR112015031878A2/pt
Priority to HK16107193.2A priority patent/HK1219222A1/zh
Priority to EA201690072A priority patent/EA201690072A1/ru
Priority to TW103125304A priority patent/TW201545773A/zh
Priority to SG11201509798PA priority patent/SG11201509798PA/en
Priority to JP2016522969A priority patent/JP2016523895A/ja
Priority to CN201480041453.7A priority patent/CN105407873A/zh
Priority to KR1020157036380A priority patent/KR101786843B1/ko
Priority to PCT/IN2014/000489 priority patent/WO2015011730A1/en
Priority to NZ714558A priority patent/NZ714558A/en
Priority to MA38865A priority patent/MA38865A1/fr
Priority to CA2917923A priority patent/CA2917923A1/en
Priority to MX2015016971A priority patent/MX374628B/es
Priority to AU2014294548A priority patent/AU2014294548B2/en
Priority to US14/899,912 priority patent/US9610277B2/en
Priority to EP14787059.6A priority patent/EP3024446A1/en
Priority to ARP140102777A priority patent/AR097067A1/es
Publication of IN2013MU02470A publication Critical patent/IN2013MU02470A/en
Priority to AP2015008876A priority patent/AP2015008876A0/xx
Priority to ZA2015/08682A priority patent/ZA201508682B/en
Priority to PH12015502802A priority patent/PH12015502802A1/en
Priority to US15/475,812 priority patent/US10098868B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN2470MU2013 2013-07-25 2013-07-25 IN2013MU02470A (enEXAMPLES)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (enEXAMPLES) 2013-07-25 2013-07-25
CA2917923A CA2917923A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent
MA38865A MA38865A1 (fr) 2013-07-25 2014-07-24 Formulation comprenant un agent hypolipidémiant
EA201690072A EA201690072A1 (ru) 2013-07-25 2014-07-24 Состав, содержащий гиполипидемическое средство
TW103125304A TW201545773A (zh) 2013-07-25 2014-07-24 包含降血脂劑的調合物
SG11201509798PA SG11201509798PA (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent
JP2016522969A JP2016523895A (ja) 2013-07-25 2014-07-24 脂質低下剤を含む製剤
CN201480041453.7A CN105407873A (zh) 2013-07-25 2014-07-24 包含降血脂剂的制剂
KR1020157036380A KR101786843B1 (ko) 2013-07-25 2014-07-24 지질 저하제를 포함하는 제제
PCT/IN2014/000489 WO2015011730A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent
MX2015016971A MX374628B (es) 2013-07-25 2014-07-24 Formulacion que comprende un agente hipolipidemico.
BR112015031878A BR112015031878A2 (pt) 2013-07-25 2014-07-24 composição farmacêutica
HK16107193.2A HK1219222A1 (zh) 2013-07-25 2014-07-24 包含降血脂药的制剂
NZ714558A NZ714558A (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent
AU2014294548A AU2014294548B2 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent
US14/899,912 US9610277B2 (en) 2013-07-25 2014-07-24 Formula comprising a hypolipidemic agent
EP14787059.6A EP3024446A1 (en) 2013-07-25 2014-07-24 Formulation comprising a hypolipidemic agent
ARP140102777A AR097067A1 (es) 2013-07-25 2014-07-25 Formulación que comprende un agente hipolipidémico
AP2015008876A AP2015008876A0 (en) 2013-07-25 2015-07-24 Formulation comprising a hypolipidemic agent
ZA2015/08682A ZA201508682B (en) 2013-07-25 2015-11-25 Formulation comprising a hypolipidemic agent
PH12015502802A PH12015502802A1 (en) 2013-07-25 2015-12-17 Formulation comprising a hypolipidemic agent
US15/475,812 US10098868B2 (en) 2013-07-25 2017-03-31 Formula comprising a hypolipidemic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (enEXAMPLES) 2013-07-25 2013-07-25

Publications (1)

Publication Number Publication Date
IN2013MU02470A true IN2013MU02470A (enEXAMPLES) 2015-06-26

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2470MU2013 IN2013MU02470A (enEXAMPLES) 2013-07-25 2013-07-25

Country Status (21)

Country Link
US (2) US9610277B2 (enEXAMPLES)
EP (1) EP3024446A1 (enEXAMPLES)
JP (1) JP2016523895A (enEXAMPLES)
KR (1) KR101786843B1 (enEXAMPLES)
CN (1) CN105407873A (enEXAMPLES)
AP (1) AP2015008876A0 (enEXAMPLES)
AR (1) AR097067A1 (enEXAMPLES)
AU (1) AU2014294548B2 (enEXAMPLES)
BR (1) BR112015031878A2 (enEXAMPLES)
CA (1) CA2917923A1 (enEXAMPLES)
EA (1) EA201690072A1 (enEXAMPLES)
HK (1) HK1219222A1 (enEXAMPLES)
IN (1) IN2013MU02470A (enEXAMPLES)
MA (1) MA38865A1 (enEXAMPLES)
MX (1) MX374628B (enEXAMPLES)
NZ (1) NZ714558A (enEXAMPLES)
PH (1) PH12015502802A1 (enEXAMPLES)
SG (1) SG11201509798PA (enEXAMPLES)
TW (1) TW201545773A (enEXAMPLES)
WO (1) WO2015011730A1 (enEXAMPLES)
ZA (1) ZA201508682B (enEXAMPLES)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007136290A1 (en) 2006-05-23 2007-11-29 Intel Corporation Millimeter-wave communication system with directional antenna and one or more millimeter-wave reflectors
CN103354757A (zh) 2011-01-31 2013-10-16 卡迪拉保健有限公司 脂肪代谢障碍的治疗
JP6246895B2 (ja) 2013-04-22 2017-12-13 カディラ・ヘルスケア・リミテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）のための新規組成物
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enEXAMPLES) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
US20180243263A1 (en) 2016-12-09 2018-08-30 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
US20220175721A1 (en) * 2019-02-13 2022-06-09 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2134686C1 (ru) 1992-07-03 1999-08-20 Смитклайн Бичам П.Л.С. Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
DE69615016T2 (de) 1995-04-28 2002-05-02 Daiichi Pharmaceutical Co., Ltd. Pentacyclische verbindungen
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
DE69828445D1 (de) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
CN100357281C (zh) 1998-05-27 2007-12-26 雷迪实验室有限公司 双环化合物、其制备方法和包含它们的药物组合物
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
JP2002527516A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
DK1250323T3 (da) 2000-01-19 2014-02-03 Cadila Healthcare Ltd Forbindelser med hypolipidemiske og hypokolesterolemiske virkninger, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende dem
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AU2001286163A1 (en) 2000-09-22 2002-04-02 Dr. Reddy's Research Foundation An improved process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
WO2005031335A1 (ja) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. 電気泳動装置および電気泳動法並びにそれを用いた生体関連物質の検出方法
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
US9931295B2 (en) * 2006-02-22 2018-04-03 Eisai R&D Management Co., Ltd. Stabilized pharmaceutical composition
US20090196923A1 (en) 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
KR101962209B1 (ko) 2009-11-26 2019-03-26 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
US8501816B2 (en) * 2010-10-12 2013-08-06 Cerecor, Inc. Antitussive compositions comprising memantine
CN103354757A (zh) * 2011-01-31 2013-10-16 卡迪拉保健有限公司 脂肪代谢障碍的治疗
JP6246895B2 (ja) 2013-04-22 2017-12-13 カディラ・ヘルスケア・リミテッド 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）のための新規組成物
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enEXAMPLES) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02828A (enEXAMPLES) 2013-08-29 2015-07-03 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives

Also Published As

Publication number Publication date
ZA201508682B (en) 2017-03-29
EP3024446A1 (en) 2016-06-01
PH12015502802A1 (en) 2016-03-14
AU2014294548A1 (en) 2015-12-17
US9610277B2 (en) 2017-04-04
MA38865A1 (fr) 2017-12-29
TW201545773A (zh) 2015-12-16
EA201690072A1 (ru) 2016-06-30
SG11201509798PA (en) 2016-02-26
KR20160013150A (ko) 2016-02-03
AU2014294548B2 (en) 2017-08-10
JP2016523895A (ja) 2016-08-12
WO2015011730A1 (en) 2015-01-29
CN105407873A (zh) 2016-03-16
CA2917923A1 (en) 2015-01-29
US10098868B2 (en) 2018-10-16
US20160136131A1 (en) 2016-05-19
BR112015031878A2 (pt) 2017-07-25
NZ714558A (en) 2017-02-24
KR101786843B1 (ko) 2017-10-18
AR097067A1 (es) 2016-02-17
AP2015008876A0 (en) 2015-11-30
MX374628B (es) 2025-03-06
HK1219222A1 (zh) 2017-03-31
MX2015016971A (es) 2016-04-25
US20170266158A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
AP2016009275A0 (enEXAMPLES)
BR102016010778A2 (enEXAMPLES)
BR112015007533A2 (enEXAMPLES)
BR112014017733A2 (enEXAMPLES)
BR112014018502A2 (enEXAMPLES)
BR112014017739A2 (enEXAMPLES)
BR112014019326A2 (enEXAMPLES)
BR112014018516A2 (enEXAMPLES)
BR112014017855A2 (enEXAMPLES)
BR112014018480A2 (enEXAMPLES)
BR112014017765A2 (enEXAMPLES)
BR112014017669A2 (enEXAMPLES)
BR112014021878A2 (enEXAMPLES)
BR112014018468A2 (enEXAMPLES)
BR112014017901A2 (enEXAMPLES)
BR112014019204A2 (enEXAMPLES)
BR112014018207A2 (enEXAMPLES)
BR112015015948A2 (enEXAMPLES)
BR112014017722A2 (enEXAMPLES)
BR112014017653A2 (enEXAMPLES)
IN2013MU02470A (enEXAMPLES)
BR112014018578A2 (enEXAMPLES)
BR112014018483A2 (enEXAMPLES)
BR112014017794A2 (enEXAMPLES)
BR112014017601A2 (enEXAMPLES)